STOCK TITAN

Moderna (MRNA) SEC Filings, Jul-Aug 2025

MRNA NASDAQ

Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.

Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.

Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
current report
-
Form 4
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.83%
Tags
insider

FAQ

How many Moderna (MRNA) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Moderna (MRNA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Moderna (MRNA)?

The most recent SEC filing for Moderna (MRNA) was filed on November 16, 2026.